Aberg, Judith A.
Shepherd, Bronagh
Wang, Marcia
Madruga, Jose V.
Mendo Urbina, Fernando
Katlama, Christine
Schrader, Shannon
Eron, Joseph J.
Kumar, Princy N.
Sprinz, Eduardo
Gartland, Margaret
Chabria, Shiven
Clark, Andrew
Pierce, Amy
Lataillade, Max
Tenorio, Allan R.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Week 240 Efficacy and Safety of Fostemsavir Plus Optimized Background Therapy in Heavily Treatment-Experienced Adults with HIV-1
https://doi.org/10.1007/s40121-023-00870-6
Article History
Received: 2 July 2023
Accepted: 4 September 2023
First Online: 26 September 2023
Declarations
:
: Judith A. Aberg has received grants from Emergent BioSolutions, Frontier Technologies, Gilead, GSK, Janssen, Merck, Pfizer, Regeneron, and ViiV Healthcare, which were paid to her institution, and participated in scientific advisory boards for GSK, Merck, and ViiV Healthcare. Bronagh Shepherd and Marcia Wang are employees of and may own stock in GSK. Jose V. Madruga has received grants for participation in scientific advisory boards from Gilead, GSK, Janssen, MSD, and ViiV Healthcare; sponsorship to attend international congresses from Gilead and Janssen; personal fees for lectures from Gilead, GSK, Janssen, MSD, Pfizer, and ViiV Healthcare; and has served as an investigator in clinical trials sponsored by Gilead, GSK, Janssen, MSD, Pfizer, Sanofi, and ViiV Healthcare. Fernando Mendo Urbina has received honoraria from Johnson and Johnson. Christine Katlama has received grants and/or personal fees from ViiV Healthcare, Gilead, and MSD. Shannon Schrader has received honoraria from Gilead and Janssen. Joseph J. Eron has received grants from Gilead, Janssen, and ViiV Healthcare, which were paid to his institution, and consultant fees from Gilead, Merck, and ViiV Healthcare. Princy N. Kumar has received grants from Eli Lilly, GSK, Merck, Gilead, Regeneron, American Gene Technologies, and BioHaven, which were paid to her institution; participated in data safety monitoring/advisory boards for Johnson & Johnson, ViiV Healthcare, Gilead, TheraTechnologies, and Merck; and holds stock/stock options in Merck, Johnson & Johnson, GSK, Gilead, Pfizer, and Moderna. Eduardo Sprinz has received grants for participation in scientific advisory boards from Abbott, Gilead, GSK, Janssen, MSD, Roche, and ViiV Healthcare. Margaret Gartland, Shiven Chabria, Andrew Clark, Amy Pierce, Max Lataillade, and Allan R. Tenorio are employees of ViiV Healthcare and may own stock in GSK.
: BRIGHTE was performed in accordance with the Declaration of Helsinki. Study protocols, amendments, and other required documents were reviewed and approved by national, regional, and/or institutional review boards or ethics committees (see Supplementary Material for list of ethics committees). All participants provided written informed consent before study initiation.